NEW YORK, June 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). CLASS PERIOD: March 7, 2024 to March 3, 2025 Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/ ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against PepGen Inc. for allegedly making false and misleading statements regarding the effectiveness and safety of its drug PGN-EDO51 and the CONNECT2 study [4]. - Investors who purchased PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - The deadline to move the Court to serve as lead plaintiff is August 8, 2025 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of misleading statements regarding the effectiveness and safety of its drug PGN-EDO51, which has led to significant stock price declines and a federal securities class action [2][4]. Group 1: Allegations and Legal Actions - The complaint against PepGen alleges violations of federal securities laws, including false statements about the effectiveness and safety of PGN-EDO51 and deficiencies in the CONNECT2 study [4]. - Investors are reminded of the August 11, 2025 deadline to seek the role of lead plaintiff in the federal securities class action against PepGen [2][12]. - The law firm encourages anyone with information regarding PepGen's conduct to come forward, including whistleblowers and former employees [13]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted the results were below expectations, leading to a 32.69% drop in stock price [5][6]. - A clinical hold notice from the FDA on December 16, 2024, raised concerns about the CONNECT2 study, resulting in a 3.63% decline in stock price [7][8]. - Following updates on safety concerns and a voluntary pause of the CONNECT2 study, PepGen's stock fell by 21.74% on January 30, 2025, and by 18.86% on March 4, 2025 [9][10]. - On May 28, 2025, PepGen announced that PGN-EDO51 did not achieve target dystrophin levels and decided to discontinue its DMD programs [11].

Core Viewpoint - A class action has been filed against PepGen Inc. for allegedly misleading investors regarding the effectiveness and safety of its drug candidate PGN-EDO51, which is intended for treating Duchenne muscular dystrophy [1][2]. Company Overview - PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases [1]. Allegations - The complaint alleges that PepGen failed to disclose critical information about PGN-EDO51, including its lower effectiveness and safety compared to what was communicated to investors [2]. - It is claimed that the CONNECT2 study was either dangerous or deficient for FDA approval, leading to the likelihood of halting the study and overstating the drug's clinical, regulatory, and commercial prospects [2]. Stock Price Impact - Following a press release on January 29, 2025, which highlighted safety concerns in the CONNECT1 study and FDA issues with the CONNECT2 study, PepGen's stock price dropped by $0.40, or 21.74%, closing at $1.44 per share on January 30, 2025 [3]. - On March 4, 2025, after announcing a voluntary pause of the CONNECT2 study, the stock price fell by $0.53, or 18.86%, closing at $2.28 per share [4]. Class Action Participation - Shareholders may be eligible to participate in the class action against PepGen, with a deadline to file a motion for lead plaintiff by August 8, 2025 [5].

Core Viewpoint - A class action securities lawsuit has been filed against PepGen Inc. due to alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that PepGen's lead product candidate, PGN-EDO51, was misrepresented as being more effective and safe than it actually is [2]. - It is alleged that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [2]. - The complaint asserts that the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - A class action lawsuit has been filed against PepGen Inc. for alleged violations of the Securities Exchange Act of 1934, concerning misrepresentations about the effectiveness and safety of its lead product candidate, PGN-EDO51 [1][3]. Group 1: Legal Action Details - The complaint was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased PepGen securities between March 7, 2024, and March 3, 2025 [1]. - Investors are encouraged to join the class action lawsuit and can contact the Investor Relations Manager for more information [3][4]. Group 2: Company Background - Bernstein Liebhard LLP, the law firm representing the investors, has recovered over $3.5 billion for its clients since 1993 and has a strong track record in class action litigation [5].

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=153444&from=3 CLASS PERIOD: March 7, 2024 to March ...

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submissio ...

A lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired the securities of PepGen between March 7, 2024 and March 3, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG ...

NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=152957&from=4CLASS PERIOD: March 7, 2024 to March 3, 2025 ...